Clinical Trial

ClimAIr: AI to Assess the Impact of Pollution and Climate on Respiratory Health in Europe

Study acronym: ClimAIr
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The ClimAIr project will expand the evidence-based understanding of climate change, air pollution, and non-communicable respiratory diseases by using Artificial Intelligence (AI) tools. It will gather data on greenhouse gases levels and disaster risks, information on serious air pollutants and respiratory diseases' prevalence. The AI powered tools will be employed to generate better intervention methods and improve public health outcomes. Federated Learning (FL) will be used to develop AI models to protect patients' privacy. By raising public awareness and delivering the ClimAIr tool - specifically designed to health workers, urban planners and policy makers - the project aims to influence policy decisions, promote healthier environments, and reduce respiratory diseases in Europe, which will be tested and validated the ClimAIr tool in specific municipalities that are part of the project. ClimAIr draws on a consortium of 21 partners from 15 European countries, including carefully selected health centres across Europe - in Spain, Luxembourg, Ukraine, Italy, France, Germany, Greece, Romania and Poland - focused on respiratory diseases, which will provide disease data and explore metabolic routes of the studied contaminants/diseases. ClimAIr is composed of an interdisciplinary team formed by research centres, ethical AI and modelling experts, SSH specialists, municipal governance, and a Communication \& Dissemination (C\&D) expert team dedicated to achieving and spread the results of the project.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-30; most recent amendment 2025-12-09.
Trial Details
NCT Number NCT07107009
Lead Sponsor Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Collaborators: Theramed Healthcare SRL (Romania), Centre Hospitalier Universitaire de Toulouse, FRANCE, Charite-Universitaetsmedizin Berlin (Germany), Aristotelio Panepistimio Thessalonikis (Greece), Uniwersytet Medyczny w Lodzi (Poland), Universita degli Studi di Milano (Italy), Bukovinian State Medical University (Ukraine), Luxembourg Institute of Health, Andaluz Health Service
Conditions Allergic Rhinitis, Asthma
Enrollment 1,906 participants
Start Date 2026-01
Primary Completion 2026-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-17